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Treatment of Intrabony Defects With an
Enamel Matrix Protein Derivative or
Bioabsorbable Membrane: An 8-Year
Follow-Up Split-Mouth Study
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and Michel Brecx*
Background: Treatments with either an enamel matrix protein deriva-
tive (EMD) or guided tissue regeneration (GTR) have been shown to pro-
mote periodontal regeneration. However, until recently, only limited data
have been available on the long-term clinical results following these re-
generative techniques. Therefore, the aim of this study was to present
the 8-year results of a prospective, controlled, split-mouth clinical study
evaluating the treatment of intrabony defects with EMD or GTR.
Methods: Ten patients, each of whom displayed one pair of intrabony
defects located contralaterally in the same jaw, were randomly treated
with EMD or with GTR by means of bioabsorbable membranes. The fol-
lowing clinical parameters were evaluated at baseline and at 1 and 8 years
after treatment: plaque index (PI), gingival index (GI), bleeding on prob-
ing (BOP), probing depth (PD), gingival recession (GR), and clinical
attachment level (CAL). The primary outcome variable was CAL. No
statistically significant differences between the groups were found at
baseline.
Results: The sites treated with EMD demonstrated a mean CAL change
from 9.5 – 1.2 mm to 6.3 – 1.3 mm (P <0.001) and 6.7 – 1.6 mm
(P <0.001) at 1 and 8 years, respectively. No statistically significant dif-
ferences were found between the 1- and 8-year results. Sites treated
with GTR showed a mean CAL change from 9.7 – 1.3 mm to 6.7 – 0.9 mm
(P <0.001) at 1 year and 6.8 – 1.2 mm (P <0.001) at 8 years. The CAL
change between 1 and 8 years did not present statistically significant dif-
ferences. Between the treatment groups, no statistically significant differ-
ences in any of the investigated parameters were observed at 1 and at
8 years. However, the study does not have the statistical power to rule
out the possibility of a difference between the two groups.
Conclusions: Within their limits, the present results indicate the fol-
lowing: 1) the clinical improvements obtained following treatment with
EMD or GTR can be maintained over a period of 8 years; and 2) further
studies of much higher power need to be performed to support equiva-
lence. J Periodontol 2006;77:1879-1886.
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T
he goal of regenerative
periodontal therapy is
to fully restore the
tooth’s supporting apparatus
that has been lost following
inflammatory periodontal dis-
ease or injury. It is character-
ized by the formation of new
cementum with inserting col-
lagen fibers, new periodontal
ligament, and new alveolar
bone.1
Several treatment modal-
ities, such as the use of dif-
ferent types of bone grafts,
root surface demineralization,
guided tissue regeneration
(GTR), growth factors, or the
application of an enamel ma-
trix protein derivative (EMD),
have been employed with
varying degrees of success to
predictably accomplish this
goal.2-7TreatmentwithGTRin-
volves the placement of a bio-
absorbable or non-resorbable
barrier membrane over the
periodontal defects and de-
nuded root surfaces, thus al-
lowing periodontal ligament
(PDL) and bone cells to selec-
tively repopulate the isolated
spaces.5 The rationale for
the clinical use of EMD is the
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observation that enamel matrix proteins (EMPs) are
deposited along the surface of developing tooth roots
prior to cementum formation.7 It has been suggested
that EMPs are involved in the formation of acellular ex-
trinsic fiber cementum and may trigger the differenti-
ation of progenitor cells into cementoblasts.7 EMD
may upregulate intracellular cyclic adenosine 39:59-
monophosphate (cAMP) levels that induce the syn-
thesis and secretion of transforming growth factor
(TGF)-b and interleukin (IL)-6 in cultured PDL cells
and gingival fibroblasts.8,9 Recent data have also indi-
cated that EMD may contain additional mitogenic fac-
tors such as TGF-b and bone morphogenetic protein
(BMP)-like growth factors that stimulate fibroblastic
proliferation and contribute to the induction of biomi-
neralization during periodontal regeneration.10-13
Observations from human histologic case reports
have provided evidence that periodontal regeneration
may be accomplished following treatment with GTR
or EMD.14-23 Data from controlled clinical studies
have shown that both therapies may lead to an addi-
tional gain of clinical attachment level (CAL) com-
pared to open flap debridement (OFD) alone.24-34
On the other hand, no significant differences were
found between treatment with EMD or GTR in intra-
bony defects.26,28,30,35-38
Clinical studies on GTR have indicated that the
short-term results can be maintained on a long-term
basis in the great majority of cases.39-48 On the other
hand, data presenting the long-term outcome follow-
ing the treatment of intrabony defects with EMD are
still limited.44,45,49-54 Moreover, there are virtually
no data from comparative, controlled clinical studies
evaluating the treatment of intrabony defects with
EMD or GTR over a period up to 8 years.
Therefore, the aim of the present controlled clinical
trial was to present the clinical results obtained at 8




The study population and the short-term (8-month
data) and 4-year results have been described in detail
previously.35,44 Briefly, a total of 16 patients (six fe-
males and 10 males) were included in the study based
on a signed informed consent. The study was in accor-
dance with the Helsinki Declaration of 1975, as re-
vised in 1983. However, only 10 patients (six females
and four males) with a mean age of 46 – 7.5 years
(range, 38 to 55 years) completed the 8-year evalua-
tion. The other six patients were lost during follow-up:
three patients refused to participate in the evaluation,
and three patients moved away. Therefore, only data
from the 10 available patients are presented in the fol-
lowing study.
Patient Selection and Investigated Parameters
The criteria for the selection of the patients were as fol-
lows: 1) presence in the same jaw of one pair of con-
tralateral intrabony defects similar in form and size as
observed on radiographs: the intrabony defects pre-
sented a depth ‡6 mm when measured with a manual
periodontal probe;i 2) no systemic diseases; 3) no use
of antibiotics for the last 6 months prior to treatment;
4) no treatment of periodontitis for the last 2 years;
and 5) a good level of oral hygiene. As criteria for a
good level of oral hygiene a plaque index (PI) score
<155 was chosen. Three months prior to surgery, each
patient was given thorough oral hygiene instructions
and full-mouth supra- and subgingival scaling and
root planing under local anesthesia.
One week prior to and after 1 and 8 years following
therapy the following clinical parameters were as-
sessed in the whole mouth by the same blinded and
previously calibrated investigator: PI and gingival in-
dex (GI),55 bleeding on probing (BOP), probing depth
(PD), gingival recession (GR), and CAL. The mea-
surements were made at six sites per tooth: mesio-
buccal (mb), mid-buccal (m), disto-buccal (db),
mesio-lingual (ml), mid-lingual (l), and disto-lingual
(dl). In the calculations, only one site representing
the same deepest point of the defect was included.
The cemento-enamel junction (CEJ) was used as
the fixed reference point. In cases where the CEJ was
not clearly visible, a restoration margin was used for
these measurements. The same periodontal probe¶
was used for all measurements. Prior to the surgery
and at 1 and 8 years after treatment, periapical radi-
ographs of the experimental sites were taken with the
long-cone parallel technique.
Surgical Procedure
All operative procedures have been described in detail
previously.35 Briefly, all treatments were performed
by the same operator (AS). Following intracrevicular
incisions, full-thickness mucoperiosteal flaps were
raised buccally and lingually. The granulation tissue
was removed from the defects, and the roots were
thoroughly scaled and planed. During surgery, the fol-
lowing measurements were made: the distance from
the cemento-enamel junction to the bottom of the de-
fect (CEJ-BD) and distance from the CEJ to the most
coronal extension of the alveolar bone crest (CEJ-
BC). The intrabony component (INTRA) of the defects
was defined as (CEJ-BD) - (CEJ-BC).
Subsequently, the defects were randomly assigned
to treatment with EMD or GTR. When EMD was used,
the root surfaces adjacent to the defects were condi-
tioned for 2 minutes with 24% EDTA gel (pH 6.7)#
i PCP 12, Hu-Friedy, Chicago, IL.
¶ PCP 12, Hu-Friedy.
# PrefGel, Straumann, Basel, Switzerland; previously, Biora, Malmo¨,
Sweden.
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to remove the smear layer.56 The defects and the
adjacent mucoperiosteal flaps were thoroughly rinsed
with sterile saline to remove any residual EDTA.
EMD** was applied on the root surfaces and into the
defects, according to the instructions given by the
manufacturer, and the flaps were repositioned coro-
nally and closed with vertical or horizontal mattress
sutures. Following a period £2 weeks, the contralat-
eral intrabony defects were treated with a bioabsorb-
able membrane.†† At these sites, the root surfaces
were scaled and root planed, but no root condition-
ing with EDTA was performed. The membrane was
trimmed and adapted over the defect in such a man-
ner that the entire defect and 2 to 3 mm of the sur-
rounding alveolar bone were completely covered.
The membrane was fixed to the same or to the neigh-
boring teeth with bioabsorbable sutures.‡‡ Flap clo-




All patients received antibiotics for 7 days (3· 375 mg
amoxicillin · 3· 275 mg metronidazole per day).57
Sutures were removed 14 days after the surgery.
The postoperative care consisted of 0.2% chlorhexi-
dine digluconate solution rinses twice a day for 6
weeks. Only after this period was toothbrushing re-
sumed in the operated areas. Recall appointments
were scheduled every second week during the first 2
months following the surgical procedure, and the pa-
tients were recalled once per month during the first
year postoperatively. After the first year and during
the rest of the observation period of 8 years, the pa-
tients were recalled every 3 or 6 months. The recall
appointments consisted mainly of reinforcement of
oral hygiene measures and professional supragingi-
val tooth cleaning.
Statistical Analysis
The statistical analysis was performed using a soft-
ware program.§§ The study was designed for testing
superiority. The primary outcome variable was CAL.
In these calculations, only the same deepest site per
tooth was included. The paired t test was used to com-
pare the data from the baseline to those at 1 and 8
years for each treatment group. Comparisons be-
tween treatment groups at baseline and at 1 and 8
years were accomplished with the paired t test. The
a error was set at 0.05. The power of the study, given
1 mm as a significant difference between groups, was
calculated to be 0.60.
RESULTS
The observations on the early postoperative healing
were described in detail elsewhere.35 No adverse re-
actions related to the EMD or the bioabsorbable mem-
brane were observed.
At baseline, there were no statistically significant
differences in any of the investigated clinical param-
eters (Tables 1 through 3).
The PI, GI, and BOP for both treatment groups at
baseline and after 1 and 8 years are summarized in Ta-
ble 1. The mean PI did not reveal a statistically signif-
icant difference between the two groups at baseline
and after 1 and 8 years. Although the PI increased
slightly in both treatment groups at 8 years, this differ-
ence was not found to be statistically significant com-
pared to the baseline or 1-year results. A statistically
significant difference was observed in both treatment
groups when comparing the GI and BOP values at
1 and 8 years to the baseline values (P <0.001).
However, no statistically significant differences were
observed between the 1- and 8-year results (Table 1).
The baseline defect characteristics are presented in
Table 2. No statistically significant difference in the
initial depth of the intrabony component was found
between the two groups. The distribution of the de-
fects according to their configuration is presented in
Table 4.
The PD, GR, and CAL at baseline and 1 and 8 years
after treatment are presented in Table 3. At 1 year, the
PD decreased statistically highly significantly in both
groups (P <0.001). Between the groups, no statisti-
cally significant difference was found. At 8 years, a
statistically significant increase in PD was observed
in both groups (P <0.05) compared to the 1-year val-
ues. At 8 years, the PD was still statistically highly sig-
nificantly improved compared to baseline (P <0.001).
At 1 year, the GR increased statistically highly sig-
nificantly (P <0.001) in both groups compared to
baseline, but the difference between the groups was
not significant (Table 3). No statistically significant
difference was found in the GR between baseline
and 8 years. The 8-year GR values improved in both
groups compared to the 1-year results, but the differ-
ence reached statistical significance only in the GTR
group (P <0.05). No statistically significant differ-
ences between the two groups were found at 8 years.
At 1 and at 8 years, the CAL improved statistically
highly significantly in both groups compared to base-
line (P <0.001) (Table 3). Within the groups and be-
tween the two treatments, no statistically significant
differences between the 1- and 8-year results were
found.
In the EMD group, two defects lost 2 mm of the CAL
gained at 1 year, whereas a CAL loss of 2 mm was
measured at 1 defect of the GTR group.
** Emdogain, Straumann; previously, Biora.
†† Resolut, W.L. Gore & Associates, Inc., Flagstaff, AZ.
‡‡ Dexon II, Davis & Geck, Manati, PR.
§§ SPSS for Windows 95, SPSS, Chicago, IL.
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DISCUSSION
The results of the present study have shown that the
treatment of intrabony defects with EMD or GTR re-
sults in significant reductions in PD and gains of
CAL that can be maintained over a period of 8 years.
No statistically significant differences between the two
treatment modalities in any of the investigated clinical
parameters were found at 1 and 8 years after therapy.
In both groups, a slight but not statistically significant
loss of mean CAL was measured between the 1- and
8-year evaluation periods. On one hand, this slight
loss of mean CAL may probably be attributed to the
2 mm of CAL loss that occurred in both groups at
some of the defects (i.e., at two defects treated with
EMD and at one defect treated with GTR). On the other
hand, in both groups, the mean PD increased statisti-
cally significantly from 1 to 8 years, whereas the mean
GR showed a tendency for improvement in the same
time. In both treatment groups, the statistically signif-
icant increase in PD between 1 and 8 years can be ex-
plained by the higher values of PI, which were slightly
higher than the baseline values. Although at 8 years
the increase in mean PI, GI, and BOP did not reach
statistical significance compared to the baseline and
1-year values, it cannot be excluded that the plaque
accumulation might have led to inflammation and loss
of CAL. Results from controlled clinical studies have
shown that the stability of gained clinical attachment
following conventional and regenerative periodontal
therapy is dependent upon stringent oral hygiene
Table 1.
PI, GI, and BOP at Baseline and 1 and 8 Years Following Treatment With EMD or GTR
Parameter Treatment Baseline 1 Year P Value 8 Years P Value
PI (mean – SD) EMD 0.8 – 0.5 0.8 – 0.4 NS 1.2 – 0.6 NS
GTR 0.7 – 0.7 0.8 – 0.5 NS 1.1 – 0.3 NS
GI (mean – SD) EMD 1.6 – 0.4 0.6 – 0.5 <0.001 1.0 – 0.7 NS
GTR 1.7 – 0.5 0.7 – 0.6 <0.001 1.0 – 0.8 NS
BOP EMD 52% 33% <0.001 37% NS
GTR 50% 34% <0.001 39% NS
NS = not statistically significant. No significant differences between the EMD and GTR groups were found.
Table 2.
Baseline Defect Characteristics (mm, mean – SD)
Treatment PD GR CAL CEJ-BD CEJ-BC INTRA
EMD 8.1 – 0.7 1.4 – 1.1 9.5 – 1.2 10.2 – 1.5 6.2 – 1.4 4.0 – 1.5
GTR 8.2 – 1.0 1.5 – 1.7 9.7 – 1.3 10.6 – 1.6 6.5 – 1.3 4.1 – 1.4
Table 3.
Clinical Parameters (mean – SD) at Baseline and 1 and 8 Years Following Treatment With
EMD or GTR
Parameter Treatment Baseline 1 Year P Value 8 Years P Value
PD EMD 8.1 – 0.7 4.0 – 0.8 <0.001 4.7 – 1.2 <0.05
GTR 8.2 – 1.0 3.6 – 0.5 <0.001 4.5 – 0.8 <0.05
GR EMD 1.4 – 1.1 2.3 – 0.8 <0.001 2.0 – 0.6 NS
GTR 1.5 – 1.7 3.1 – 1.0 <0.001 2.3 – 1.2 <0.05
CAL EMD 9.5 – 1.2 6.3 – 1.3 <0.001 6.7 – 1.6 NS
GTR 9.7 – 1.3 6.7 – 0.9 <0.001 6.8 – 1.2 NS
NS = not statistically significant. No significant differences between the EMD and GTR groups were found.
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and compliance with a supportive periodontal care
program.41,46,58 Furthermore, it has to be noted that
only 10 out of the original 16 patients were included in
the present follow-up study. Thus, it is unknown to
what extent the lack of six patients might have influ-
enced the 8-year results. Another important factor
that was demonstrated to strongly influence the
outcome of regenerative periodontal treatment is
smoking.58 However, due to the fact that none of the
10 patients was a smoker, no conclusion can be drawn
regarding this issue.
Taken together, these observations may also sug-
gest that a remodeling of the soft tissues may take
place without major changes in CAL on a long-term
basis. Similar observations were made in other studies
evaluating the long-term outcome of conventional
and regenerative periodontal therapy.45,52,59,60 It is
also important to realize that the study does not have
the statistical power to rule out the possibility of a dif-
ference between the two groups. Further studies of
much higher power need to be performed to support
equivalence and to evaluate the possible factors af-
fecting periodontal tissue remodeling on a long-term
basis.61
The finding that the treatment of intrabony defects
with EMD may result in statistically significantly im-
provements in PD and CAL compared to baseline
on a short-term basis is in agreement with previously
reported data.25-38 To the best of our knowledge,
there are no other data from prospective, controlled
clinical studies reporting the outcome of EMD treat-
ment up to an 8-year period. In the first controlled clin-
ical trial comparing the treatment of intrabony defects
with EMD to that with flap surgery, Heijl et al.25 re-
ported a mean CAL gain of 2.1 mm after treatment
with EMD and of 1.5 mm after flap surgery alone (con-
trol) at 8 months. At 36 months, the mean CAL gain
was 2.2 mm for EMD-treated sites and 1.7 mm for
controls. At 1 and 8 years, the mean CAL gains ob-
tained in the present study were higher than that re-
ported by Heijl et al.25 Factors contributing to this
difference might be the defect type and the initial
depth of the defect. In the present study, the majority
of defects were 2-wall defects, whereas the defects in
the study by Heijl et al.25 displayed a predominantly
1-wall configuration. Results from controlled clinical
studies have provided evidence that 2- and 3-wall de-
fects have a greater healing potential than 1-wall de-
fects after conventional and regenerative periodontal
surgery.58,62 Furthermore, in the present study, the
mean initial defect depth was somewhat higher than
in the previously mentioned study.25 Clinical studies
have demonstrated that the CAL gain after any type
of periodontal treatment is strongly dependent upon
the initial PD (i.e., the deeper the initial defect, the
greater the PD reduction and CAL gain).33,58-60 The
present results are in agreement with recent data from
case reports and controlled clinical studies evaluating
the long-term treatment of intrabony defects with
EMD.44,45,49-54 In a 4-year follow-up study, a total
of 46 intrabony defects in 33 patients were consecu-
tively treated with EMD.52 At 4 years, the results indi-
cated a stability of the 1-year results. Moreover, the
reentry surgery performed after 4 years in one case
demonstrated an almost complete fill of the intrabony
component. These findings are in line with very recent
observations made in three cases reentered after 7
years following treatment with EMD.54 Furthermore,
results from a prospective, controlled clinical study
evaluating the treatment of intrabony defects with
EMD, GTR, EMD plus GTR, and OFD have shown that
the short-term clinical results following these treat-
ments can be maintained over a period of 5 years.45
Thus, the present 8-year results are consistent with
those reported by others after 3, 4, 5, and 7 years and
indicate that the obtained clinical results with EMD
may be maintained even up to 8 years when an ade-
quate plaque control program is maintained.44,45,49-54
The present results obtained with GTR are also in
agreement with those from other clinical studies that
indicate that the clinical improvements obtained fol-
lowing treatment with GTR can be maintained over
a longer time period if an optimal patient and defect
selection are accomplished.39-48 A recent retrospec-
tive study evaluated a total of 175 patients with one
deep intrabony defect treated with GTR. The results
suggested that the clinical improvements obtained
following the treatment of intrabony defects with
GTR can be maintained over a period of up to 16
years; thus, this treatment approach represents an
important modality for maintaining severely compro-
mised teeth.46
However, it should be also pointed out that the ex-
posure of the membrane material, which is a common
complication in GTR therapy, is absent following
treatment with EMD.38,63 This fact, coupled with the
finding that both treatments have been shown to result
in comparable histologic and clinical results, may
suggest that treatment with EMD might be preferred
Table 4.
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to GTR from a clinical point of view, especially in cases
where the defects are self-containing and an adequate
membrane fixation and soft tissue coverage are tech-
nically demanding.19,38,64
CONCLUSION
Within their limits, the present results indicate the fol-
lowing: 1) the clinical improvements obtained follow-
ing treatment with EMD or GTR can be maintained
over a period of 8 years, and 2) further studies of much
higher power need to be performed to support equiv-
alence.
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